Sanofi inaugurates Lantus SoloSTAR Pen assembly plant in China

28 May 2012

French drug major Sanofi (Euronext: SAN) revealed this morning that it has inaugurated a new assembling and packaging line to produce its pre-filled insulin injection pen Lantus (insulin glargine) SoloSTAR at its Beijing, China, plant.

Presiding over the inauguration ceremony, chief executive Christopher Viehbacher announced the second phase of the $90 million project to install a high-tech cartridge aseptic production line. With a designed capacity of 48 million units per year, the facility is expected to help fulfil the needs of people with diabetes and ultimately improve the standard of diabetes care in China.

The Lantus investment, announced three years ago (The Pharma Letter April 22, 2009), follows a $94.0 million investment that the Paris-based firm made in 2007 to establish a high-tech manufacturing facility to produce Vaxigrip for the prevention of seasonal influenza and to contribute to pandemic readiness in China. Sanofi now has a total of six manufacturing plants in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK